Novartis (VTX:NOVN) PT Set at CHF 90 by Deutsche Bank

Deutsche Bank set a CHF 90 price objective on Novartis (VTX:NOVN) in a report released on Friday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

A number of other research firms have also recently commented on NOVN. JPMorgan Chase & Co. set a €50.00 ($58.14) price target on shares of Brenntag and gave the stock a buy rating in a report on Tuesday, July 16th. Morgan Stanley upped their price target on shares of Intact Financial from C$125.00 to C$128.00 in a report on Thursday, May 30th. HSBC set a €101.00 ($117.44) price target on shares of Grenke and gave the stock a buy rating in a report on Thursday, April 25th. Goldman Sachs Group began coverage on shares of Enbridge in a report on Thursday. They issued a neutral rating on the stock. Finally, Credit Suisse Group cut their price target on shares of FOX from $51.00 to $45.00 and set an outperform rating on the stock in a report on Monday, June 3rd. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of CHF 88.64.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: What is total return in investing?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.